Amneal and Metsera Collaborate to Develop and Supply Next-Generation Medicines for Obesity and Metabolic Diseases
Amneal and Metsera Collaborate to Develop and Supply Next-Generation Medicines for Obesity and Metabolic Diseases
10/01/24, 10:05 AM
Money
$200 million
Type
partnership
Amneal Pharmaceuticals, Inc. and Metsera, Inc. have announced a collaboration agreement to develop and supply a portfolio of new weight loss medicines for obesity and metabolic diseases. Amneal will serve as Metsera's preferred supply partner for developed markets and will also commercialize Metsera's products in select emerging markets
Company Info
Additional Info
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com.